Drug Database
QL

QL-1209 (QL1209 / QL 1209)

✓ Approved

Qilu Pharmaceutical · ERBB2 · Monoclonal Antibodies

What is QL-1209?

QL-1209 is a monoclonal antibodies developed by Qilu Pharmaceutical. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesQL1209, QL 1209
CompanyQilu Pharmaceutical
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetERBB2
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Qilu Pharmaceutical

Mechanism of Action

Molecular Targets

QL-1209 acts on 1 molecular target:

ERBB2erb-b2 receptor tyrosine kinase 2 (NEU, CD340)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

QL-1209 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved

Related Research Articles

PubMedThe Journal of surgical research2026-09-19

Dehiscence After Damage Control Laparotomy for Trauma: Who Is Really at Risk?

Dixon Alexandra A, Kwon Eustina G EG, Katt Sonja S, O'Connell Kathleen K et al.

Few data are available regarding fascial dehiscence after damage control laparotomy (DCL). We aimed to identify the incidence and risk factors of fascial dehiscence following DCL in the trauma population. This is a retrospective cross-sectional study from an urban academic Level I trauma institute. Adult patients, ≥14 years of age, who underwent DCL for traumatic injuries between July 1, 2017 and June 30, 2022 were included. Dehiscence was analyzed using logistic regression models to report odds ratios. A total of 251 patients met inclusion criteria. The rate of fascial dehiscence was 12.4%. Fascial dehiscence was associated with a higher positive fluid balance at time of abdominal closure (+6496 mL [interquartile range (IQR): 3923, 8853 mL] versus +3583 mL [IQR: 1209, 7877 mL]; P = 0.012), increased number of abdominal operations (3 [IQR 2, 4] versus 2 [IQR 2, 3]; P < 0.001), and presence of enteric injury (80.6% versus 50.4%; P = 0.008). In a multivariable analysis, presence of enteric injury was independently associated with 3.7-fold higher odds of fascial dehiscence. Presence of enteric injury was independently associated with increased incidence of abdominal fascial dehiscence in patients who underwent DCL for trauma. Additionally, positive fluid status at time of abdominal closure and total number of trips to the operating room prior to abdominal closure may be important factors to consider when closing an open abdomen after DCL. Although prior studies have reported on the incidence of dehiscence following DCL, this study adds to the limited data available on specific factors contributing to an increased risk of fascial dehiscence that might inform surgical decision making.

PMID 42762691
Read full article →
PubMedDiabetic medicine : a journal of the British Diabetic Association2026-09-15

Parental monitoring and therapeutic adherence in adolescents and young adults with type 1 diabetes mellitus: Systematic review with meta-analysis.

Muñoz-Cruz Juan Carlos JC, López-Martínez Catalina C, Del-Pino-Casado Rafael R

To synthesise and quantify the association between parental monitoring and therapeutic adherence in adolescents and young adults (10-24 years) with Type 1 Diabetes Mellitus (T1DM). We conducted a systematic review with meta-analysis following PRISMA guidelines (PROSPERO: CRD420251231615). Searches were conducted in PubMed, CINAHL, SCOPUS, and PsycINFO up to June 2026. Observational studies examining the association between parental monitoring (active supervision of diabetes self-management) and multidimensional therapeutic adherence in individuals aged 10-24 years with T1DM were included. Random-effects models were used to pool correlation coefficients. Heterogeneity (I2), publication bias (Egger's test and trim-and-fill method), and sensitivity analyses were assessed. Methodological quality and certainty of evidence were evaluated using predefined criteria and GRADE principles. Eight studies (8 independent samples; N = 1209) met inclusion criteria. All the studies were cross-sectional and conducted in the United States. The pooled analysis showed a significant positive association between parental monitoring and therapeutic adherence (r = 0.286; 95% CI: 0.232-0.337), with no statistical heterogeneity. Findings were consistent across informants (parent- or adolescent-reported) and remained robust in sensitivity analyses. Risk of publication bias was low and did not materially affect the estimates. Overall certainty of evidence was moderate. Parental monitoring is consistently and positively associated with therapeutic adherence in adolescents and young adults with T1DM. Although effect sizes were small to moderate and studies were cross-sectional, the findings support the clinical relevance of collaborative and non-intrusive parental supervision. Family-centred interventions promoting adaptive monitoring may help mitigate the decline in adherence during adolescence.

PMID 42741832
Read full article →
PubMedACS biomaterials science & engineering2026-09-14

Oral Nanoarmored Lactobacillus rhamnosus with Inflammation Targeting and Scavenging Activities for Colitis Lesion-Specific Therapy.

Li Wen W, Yuan Siyuan S, Wu Hongjing H, Huang Menglin M et al.

Nanoarmored probiotics with inflammation targeting and scavenging activities without complex synthetic procedure is important for maintaining their native bioactivity, yet it remains a challenge. In this work, we demonstrated the multifunctional nanoparticle (QL@PS NP)-armored Lactobacillus rhamnosus (LAB) with inflammation targeting and regulation activity for inflammatory bowel disease (IBD) treatment. QL@PS NPs were assembled by quercetin (Que), lipoic acid (LA), and phosphatidylserine (PS), which could target macrophages and degrade in reactive oxygen species (ROS)-rich lesion sites, exhibiting excellent antioxidant and anti-inflammatory capability in vitro. QL@PS NPs were coated on the surface of thiolated LAB under a cell-friendly condition, and the resulting nanoarmored probiotic (LAB@NPs) could protect LAB from the gastrointestinal assaults and ROS damage. LAB@NPs are more likely to be up-taken by macrophages, scavenging oxidative stress and regulating the inflammatory microenvironment of colitis lesions through the synergistic effect of probiotics and QL@PS NPs. In vivo experimental results certified that LAB@NPs achieved notable lesion-specific therapeutic efficacy in mouse colitis models, significantly ameliorating colon shortening, reducing inflammatory reactions and pathological tissue damage. This work provides a facile and effective strategy to construct nanoarmored probiotics for therapy of IBD.

PMID 42733202
Read full article →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-09-11

In-Situ Preparation of Nano-Si Embedded in Porous Carbon From Liquid Silicon Precursors in Molten Salt for High-Performance Lithium-Ion Battery Anodes.

Wang Yida Y, Cui Xiaoyan X, Liao Renwei R, Xia Yun Y et al.

The structures of silicon‑embedded porous carbon feature unique pore‑confinement effects and serve as highly promising configurations for silicon‑carbon anodes. However, conventional preparation technologies based on silicon sources have obvious technical shortcomings that limit the fabrication and industrial application of such composite anodes. Among them, the CVD process using silane as a precursor carries high safety risks and can easily lead to pore clogging of carbon matrices and aggregation of silicon particles. This work employs chemically stable and highly wettable polydimethylsiloxane (PDMS) as the liquid silicon source, employs biomass-derived porous carbon as a host matrix, and synthesizes silicon-embedded porous carbon anode materials through in situ low-temperature molten salt reduction (denoted as SiNPs@PC). SiNPs@PC exhibits a reversible capacity of up to 1209 mAh g-1 after 100 cycles at 0.1 A g-1. Subsequently, coating SiNPs@PC with an ionic-liquid-derived carbon layer yields SiNPs@PC1_ILs3, which delivers enhanced cycling stability and retains 82.7% of its initial capacity after 2000 long-term cycles at 5 A g-1. The in situ preparation strategy using liquid silicon source offers comprehensive advantages over CVD method in the safety, operability and cost of process.

PMID 42723401
Read full article →
PubMedPloS one2026-09-11

Evaluation of photoinhibition and development of stress tolerance index to identify photosynthetically adapted and stress tolerant germplasm accessions of tepary bean.

Suárez Juan Carlos JC, Contreras Amara Tatiana AT, Rao Idupulapati M IM

Knowledge about photosynthetic adaptation and stress tolerance in tepary bean (Phaseolus acutifolius) accessions under acidic soil and high‑temperature conditions in the Colombian Amazon is limited. We developed a stress tolerance index (STI) as a helpful scorecard based on physiological measurements of 323 accessions that were grown in acidic soil under field and screenhouse conditions and were evaluated under well‑watered and water‑stressed treatments at dawn and midday. Based on STI and complementary photosynthetic traits, accessions were classified into five adaptive categories (highly: n = 34, 10.5%; moderately: n = 49, 15.1%; slightly: n = 79, 24.4%; poorly: n = 100, 30.9%; very poorly: n = 61, 18.8%). Three accessions (G40068, G40302, G40087) stood out in overall performance: G40087 had the highest STI (0.754), G40068 the highest Fv/Fm (0.737), and G40302 the highest qL (0.562). These accessions also exhibited higher relative chlorophyll content (between 45 and 52), greater leaf thickness (between 280 and 320 μm), a maximum photochemical efficiency of about 0.73, and an effective quantum yield of >0.45 under stress-traits that supported better photosynthetic performance. These materials could serve as promising parents for breeding climate‑resilient beans adaptive to the western Amazon, but their agronomic value requires validation in yield and biomass trials under the same stress conditions.

PMID 42726716
Read full article →
PubMedBMJ open2026-09-11

Which Way? Quit Pack study protocol: a national hybrid type 2 effectiveness-implementation study of mailed smoking and vaping cessation support for Aboriginal and Torres Strait Islander people.

Booth Kade K, Bryant Jamie J, Roberts-Barker Kayden K, Mills Zabowie Z et al.

Mailed smoking and vaping cessation support provided through the Which Way? Quit Pack programme has demonstrated acceptability and preliminary effectiveness in delivering culturally grounded support. However, there is no evidence of the effectiveness of mailed cessation programmes for Aboriginal and Torres Strait Islander people when implemented on a national scale. Building on previous work, this study aims to evaluate both the implementation effectiveness and cost-effectiveness analysis of the Which Way? Quit Pack mailed smoking and vaping cessation intervention for Aboriginal and Torres Strait Islander people. A national single-group hybrid type 2 effectiveness-implementation study with 2000 Aboriginal and/or Torres Strait Islander people who use cigarettes and/or e-cigarettes (vapes) daily, want to quit and are aged ≥18 years. Participants will receive access to a culturally tailored mailed quit pack that includes up to a 12-week supply of nicotine replacement therapy, phone-based behavioural counselling and access to an online support forum. Cessation outcomes including 7-day point prevalence abstinence, prolonged abstinence and quit rates will be evaluated at 3, 6 and 12 months. An intention-to-treat approach will be used for cessation outcomes, with participants lost to follow-up classified as smokers or vapers. Exploratory logistic regression analyses will examine factors associated with quitting, and causal machine learning methods will be used to explore variation in intervention effectiveness across participant subgroups. The Reach-Effectiveness-Adoption-Implementation-Maintenance framework will guide evaluation of implementation and effectiveness outcomes. Analysis measures include cessation and quit attempt rates, number of participants recruited, representativeness and intervention uptake. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) will guide the cost-effectiveness analysis. This study is governed by Aboriginal and Torres Strait Islander leadership and community-controlled partnerships and is conducted in line with Indigenous data sovereignty and Indigenous research ethics principles. The study has also received approval from the following human research ethics committees: Aboriginal Health & Medical Research Council of NSW (2493/25), Aboriginal Health Committee South Australia (04-25-1209), the Western Australian Aboriginal Health (HREC1474), the Victorian Aboriginal Community Controlled Health Organisation (2025/HREC0061) and the University of Newcastle Human Research (H-2025-0311). Findings will be disseminated in forms determined, governed and endorsed by Aboriginal and Torres Strait Islander people and communities through the project Governance, including peer-reviewed publications, policy briefs, community-led knowledge translation activities and presentations at local, national and international conferences. ACTRN12626000459325.

PMID 42727968
Read full article →

+3367 more articles available with a free account

Sign up free to view all articles →

Ask about QL-1209